Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Gliosarcoma

• Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
• Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
• A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma
• Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
• A Phase I/II Study of Pembrolizumab and M032 (NSC 733972)
• hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
• Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
• Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
• ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
• Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
• Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
• Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma
• Mycophenolate Mofetil Combined With Radiation Therapy in Recurrent Glioblastoma
• Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
• Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
• Phase I Study of Marizomib + Panobinostat for Children With DIPG
• Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
• Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
• Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
• Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
• Sunitinib in Sarcomas of the Central Nervous System
• Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
• Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
• Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
• Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
• Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
• Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
• BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
• NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
• Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
• Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
• Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
• Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
• Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
• A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
• Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
• SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
• Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
• INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
• Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
• Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
• Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
• Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
• Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
• 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
• Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
• Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
• Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
• Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
• Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
• 3T MRI Biomarkers of Glioma Treatment Response
• Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
• p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
• Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
• ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
• BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
• A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
• Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
• Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
• Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
• Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
• Bevacizumab Beyond Progression (BBP)
• Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
• Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
• A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
• Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
• BIBF 1120 for Recurrent High-Grade Gliomas
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
• Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
• RO4929097 in Treating Patients With Recurrent Invasive Gliomas
• Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
• A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
• Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
• Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
• A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
• Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
• Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
• Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• AMG 102 and Avastin for Recurrent Malignant Glioma
• Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
• Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
• Radiosurgery Plus Bevacizumab in Glioblastoma
• Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
• Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
• Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
• GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
• Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
• Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
• Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
• MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
• Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
• Sorafenib in Newly Diagnosed High Grade Glioma
• Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
• Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
• Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
• A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
• Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
• A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
• Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
• Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
• Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
• O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
• Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
• Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
• Dose-Intense Temozolomide in Recurrent Glioblastoma
• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
• Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
• Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
• Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
• Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
• Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
• Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
• Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
• PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
• Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
• Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
• Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
• Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
• Ph I Dasatinib + Erlotinib in Recurrent MG
• Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
• Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
• Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
• Sunitinib in Treating Patients With Recurrent Malignant Gliomas
• Pazopanib in Treating Patients With Recurrent Glioblastoma
• Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
• Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
• Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
• Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
• Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
• Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
• Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
• Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
• Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
• Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
• Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
• Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
• Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
• Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
• Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
• Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
• 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
• Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
• GW572016 to Treat Recurrent Malignant Brain Tumors
• Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
• Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
• FR901228 in Treating Patients With Recurrent High-Grade Gliomas
• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
• Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
• Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
• A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
• Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
• Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
• CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
• Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Bortezomib in Treating Patients With Recurrent Glioma
• Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
• Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM